service

systems

Anavex Life Sciences Corporation

wait

Seems crazy to me to unjust approvals that are going on while we wait on legitimate results!!!

But why wait 3 years with that when Anavex 50mg dose is likely better! !

So, if one waits months for an answer and then has to resubmit to another journal it can hold things up.

This is a shitshow till data is presented.

loss

but  losses  and  disappointment  with  Missling.

$AVXL Took my $250 loss and Got out guys too much noise not enough action.

but was faked by the move and held them to expiration and had to book a loss of $19,000.

shareholder

The krout has proven to be an a hole toward shareholders.

Missling is a greedy pig, doesnt see the bad he does by delaying intentionally, not only to shareholders,

i am telling for years that we need to fire that shitty guy just here to full his pockets without any consideration for his shareholders.

.this guy doesnt respect his shareholders and he must be sue for that.

$AVXL fire Missling, he has been here 9 years and done nothing to drive shareholder value other than BS hype

$AVXL why does the company not believe they are beholden to their shareholders?

$AVXL Unfortunately the Investorshub AVXL board has deteriorated to the point that it is basically a board consisting of almost entirely FUD with almost more bashers than true shareholders.

Messling is grossly deficient in anticipating the expectations of shareholders and the market.

$AVXL as corporate shareholder, I have sent an email on dec. 21st and a friendly reminder yesterday to IR - no response yet !!

One hand he says he care for shareholder value, on other hand he is purposely not sharing updates.

shareprice

$AVXL missling next time should change a few letters when hiring and SP will improve: from FDA to FBI former employee.

$AVXL Every time Missling speaks, the SP tanks…..amateurish communication, unbelievable.

It&#39;s stupid, it wastes time (and $$$) and it leaves the company vulnerable with a supressed SP.

Based on Rett alone, SP is well under 100$, sorry to bust your ballown,but please try to stay realist and keep a little credibility!

$AVXL The sp is wrong there must be a glitch

$AVXL not that i am happy with the SP overall

$AVXL Until you realize that and admit that the presenter screwed up in rushing the presentation the SP will stay where it’s at

$AVXL wandering when we will cross ANVS SP ;) 
never again!!!!

$AVXL we didnt cross ANVS SP yet, no good haha!

show

Take your money from this shit show and deposit in your bank account.

What an absolute unregulated criminal shit show this market has become.

Missling shows poor judgement and is not suited to be ceo.

SHOWS THE EXTREME WEAKNESS AND  DISTRESS THE STOCK IS UNDER.

but need more time to evaluate and announce a conference call for Monday instead we have a shit show.

ANAVEX®2-73 might be a very much needed solution for many patients with Alzheimer&#39;s disease.&quot;  
 
Thanks for the fight in here - we won after all! https://www.proinvestor.com/boards/108268/

ANAVEX®2-73 might be a very much needed solution for many patients with Alzheimer’s disease.” 
 
THIS IS GREAT!! !

pple will be so surprised, like all BP, here is the AD solution, not anywhere else!

business-result

Anavex&#39;s A2-73 Blarcamesine&#39;s trial results on 2 previously completed adult phase-3 trials were highly successful.

But the company actually has never seen before wonderful results.

If results hold up, the stock will achieve massive gains.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

Alzheimer&#39;s is the most valuable and most difficult indication and most desired lately..  and only Anavex really has some great results with a great safety record. .

The  sava  results  trounce  you  guys  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

Sava has potential and the phase 3 results will show the truth.

drug

- Timo grimmer is in the team 
- All endpoints of the clinical trial were reached 
 
I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

we have a drug, even many drugs, good for so many indications,  to become a giant pharma, we are about to get billions in revenues.

$AVXL The improvements in the drug arm cannot be lucky. .

I&#39;m looking forward to seeing the long term AD data on ANVS and have the feeling it&#39;s going to end up being the best in class AD treatment as well.

Do not listen to any FUD this drug is the real deal.

$AVXL amazing to see the actual benefits to people and their families of this “miracle drug” as they call it

$AVXL Dr. Perry said we have a legendary drug which actually reverses AD and is safe unlike Adulhelm.

trial

$AVXL amazing  avxl  still  in  singke  digits  after  a  supposedly  amazing  “pivotal”  trial  readout  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.

$AVXL Australia trial data meets the gold standard.

2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.

This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA  eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.

SCWorx Corp

pump-and-dump

$WORX This is an example of a shitco stock that is subject to a Pump &amp; Dump scheme every 3-6 months (which never lasts).

$WORX Shorts will lose the battle and the war.

wall

short

$WORX Shorts are bagged spreading erroneous and unfounded nonsense.

SCWorx offers a technically advanced solution which has proven to be beneficial to large hospitals with challenging technical and data management issues.

SCWorx improves the flow of info quickly and accurately between the existing supply chain, electronic records, clinical systems, and patient billing functions.

Healthtech is fast growing, their client base is vast and growing including major hospital systems, clients extending and paying more, seasoned investor buying 8.2% position.

play

$IVDA  $WORX has potential for play of the month even year with a set up like this.

Now i am calling $WORX - huge 13g and bottomed chart, this will be the next big undervalue play.

$WORX The unequivocal top technology play for hospitals and medical purposes.

$WORX HOD break out in play 👀🚨🚨🚨🔜

$WORX 💎This is my favorite play right now by far, i am swinging for big gains.💎 
 
$CMPO 18% short!

float

insider

The price action is of a winner 🚨🚨🚨🚀👀
$WORX Insiders been loading.

NICE Systems Ltd.

$NICE https://www.stockilluminati.com/nice/news.php - NICE Actimize Honored for Best Anti-Money Laundering Solution by Regulation Asia’s Excellence Awards for Second Consecutive Year

$NICE NICE Actimize Honored for Best Anti-Money Laundering Solution by Regulation Asia&amp;#39;s Excellence Awards for Second Consecutive Year 

https://newsfilter.io/a/6d8bb3432f435d050baf57e1c375ffc9

$NICE 📰 NICE Actimize Launches Real-Time Money Mule Defense Solution to Detect Illicit Activity Throughout the Entire Customer Lifecycle

https://quantisnow.com/i/4196717?utm_source=stocktwits

45 seconds delayed.

$NICE NICE Actimize Launches Real-Time Money Mule Defense Solution to Detect Illicit Activity Throughout the Entire Customer Lifecycle 

https://newsfilter.io/a/17fe27d0e9b7f056d48fe5fe8f063751

$NICE NICE Workforce Management Transforms Operations for Alteram Solutions https://www.otcdynamics.com/nice-nice-workforce-management-transforms-operations-for-alteram-solutions

$NICE https://www.stockilluminati.com/nice/news.php - NICE Workforce Management Transforms Operations for Alteram Solutions

$NICE
 2023-03-07 08:00 ET 

NICE Workforce Management Transforms Operations for Alteram Solutions
https://stonkmoon.com/news/NICE/26892a709bc8d46ae7bc1b3acaa4557f

$NICE NICE / NICE Systems Ltd. Price Target Updated 
https://fintel.io/sfo/us/nice?utm_source=stocktwits.com&amp;utm_medium=referral&amp;utm_campaign=pricetarget

$NICE NICE / NICE Systems Ltd. Price Target Updated 
https://fintel.io/sfo/us/nice

NICE Named the Technology Leader in 2022 SPARK MatrixTM for Contact Center as a Service (CCaaS) Report for Second Consecutive Year https://conferencecalltranscripts.com/summary/?id=507012&amp;pr=true $NICE

NICE Named the Technology Leader in 2022 SPARK MatrixTM for Contact Center as a Service (CCaaS) Report for Second Consecutive Year https://conferencecalltranscripts.com/summary/?id=507011&amp;pr=true $NICE

NICE Named the Technology Leader in the 2022 SPARK Matrix™ for Customer Journey Analytics (CJA) Report https://conferencecalltranscripts.com/summary/?id=505930&amp;pr=true $NICE

NICE Named the Technology Leader in the 2022 SPARK Matrix™ for Customer Journey Analytics (CJA) Report https://conferencecalltranscripts.com/summary/?id=505929&amp;pr=true $NICE

NICE CXone Named Leader in Frost and Sullivan’s 2022 North American Enterprise Cloud Contact Center Report https://conferencecalltranscripts.com/summary/?id=503629&amp;pr=true $NICE

customer

$NICE LanguageLoop Implements NICE CXone to Transform its Customer Experience Operations https://www.otcdynamics.com/nice-languageloop-implements-nice-cxone-to-transform-its-customer-experience-operations

$NICE 📰 LanguageLoop Implements NICE CXone to Transform its Customer Experience Operations

https://quantisnow.com/i/4140589?utm_source=stocktwits

45 seconds delayed.

$NICE LanguageLoop Implements NICE CXone to Transform its Customer Experience Operations 

https://newsfilter.io/a/60ef51e2912d9fb42364b3315fec9b99

$NICE NICE Named the Technology Leader in the 2022 SPARK Matrix™ for Customer Journey Analytics (CJA) Report https://www.otcdynamics.com/nice-nice-named-the-technology-leader-in-the-2022-spark-matrix-for-customer-journey-analytics-cja-report

$NICE 📰 NICE Named the Technology Leader in the 2022 SPARK Matrix™ for Customer Journey Analytics (CJA) Report

https://quantisnow.com/i/4089097?utm_source=stocktwits

45 seconds delayed.

industry

$NICE 📰 NICE Announces Industry&#39;s First Conversational CX With ChatGPT-Enabled CXone

https://quantisnow.com/i/3957063?utm_source=stocktwits

45 seconds delayed.

NICE Enlighten XO Receives 2022 Industry Award from Speech Technology for Boosting Contact Center Performance with AI-Based Solutions https://conferencecalltranscripts.com/summary/?id=467304&amp;pr=true $NICE

NICE Enlighten XO Receives 2022 Industry Award from Speech Technology for Boosting Contact Center Performance with AI-Based Solutions https://conferencecalltranscripts.com/summary/?id=467303&amp;pr=true $NICE

$NICE https://www.stockilluminati.com/nice/news.php - NICE Enlighten XO Receives 2022 Industry Award from Speech Technology for Boosting Contact Center Performance with AI-Based Solutions

$NICE 📰 NICE Enlighten XO Receives 2022 Industry Award from Speech Technology for Boosting Contact Center Performance with AI-Based Solutions

https://quantisnow.com/i/3782384?utm_source=stocktwits

45 seconds delayed.

$NICE NICE Enlighten XO Receives 2022 Industry Award from Speech Technology for Boosting Contact Center Performance with AI-Based Solutions
https://www.stocktitan.net/news/NICE/nice-enlighten-xo-receives-2022-industry-award-from-speech-w1o0kvlrzwh8.html

$NICE NICE Enlighten XO Receives 2022 Industry Award from Speech Technology for Boosting Contact Center Performance with AI-Based Solutions 

https://newsfilter.io/a/42969f57fa99903b45dd6807a8f61c66

Top Stocks matching your search for "services systems"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Dec, 4, 2022

Dec, 2, 2022

WORX

SCWorx Corp

-25.75%

$0.44 - $0.33

Dec, 5, 2022

NICE

NICE Systems Ltd.

-5.46%

$222.56 - $210.41

Mar, 20, 2023

Mar, 20, 2023

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Dec, 4, 2022

Dec, 2, 2022

Oct, 18, 2022

WORX

SCWorx Corp

-25.75%

$0.44 - $0.33

Dec, 5, 2022

NICE

NICE Systems Ltd.

-5.46%

$222.56 - $210.41